Format

Send to

Choose Destination
Bone. 2015 Jan;70:62-5. doi: 10.1016/j.bone.2014.07.026. Epub 2014 Aug 28.

Targeted delivery of mesenchymal stem cells to the bone.

Author information

1
Center for Musculoskeletal Health, University of California at Davis School of Medicine, Sacramento, CA 95817, USA.
2
Center for Musculoskeletal Health, University of California at Davis School of Medicine, Sacramento, CA 95817, USA. Electronic address: nelane@ucdavis.edu.

Abstract

Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the α4β1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled "Stem Cells and Bone".

KEYWORDS:

Bone mass; Bone strength; Mesenchymal stem cells; Osteoblasts; Osteoporosis

PMID:
25173607
PMCID:
PMC4268265
DOI:
10.1016/j.bone.2014.07.026
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center